Alpelisib is a competitive selective PI3Kα inhibitor (Fig. 1) originally developed for the treatment of PIK3CA-mutated advanced breast cancer (André et al, 2019; Center for Drug Evaluation and Research, 2019). Here, PIK3CA is linked to breast carcinoma.